Covid-19 challenges US dreams for Copenhagen-based diagnostics company
In spite of Covid-19, the plans to launch in the US in 2020 is still on the table for Radiobiotics, which develops algorithms for detecting diseases on X-ray scans. The firm has entered into a new US partnership, and before the new year, it will submit an FDA application and kick off the commercialization process.
BY ALBERT RØNNING-ANDERSSON, TRANSLATED BY NIELSINE NIELSEN
Like most other companies, the digital health firm Radiobiotics from Copenhagen has been struck by the effects of the Covid-19 virus.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
